What can be expected from tumor markers in pancreatic cancer?

Clinical Pancreatology: For Practising Gastroenterologists and Surgeons

Volumn , Issue , 2007, Pages 377-382

  Seufferlein, Thomas ^a   Adler, Guido ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

CA 19 9; Genetic markers; Pancreatic cancer; Telomerase; Tumor markers

Indexed keywords

EID: 84889616998     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987506.ch45     Document Type: Chapter

References (25)

1. Andrianifahanana M, Moniaux N, Schmied BM et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 2001;7:4033-4040.
2. Argani P, Iacobuzio-Donahue C, Ryu B et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-3868.
3. Biankin AV, Morey AL, Lee CS et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002;20:4531-4542.
4. Buchholz M, Boeck W, Fensterer H. Use of DNA arrays/microarrays in pancreatic research. Pancreatology 2001;1: 581-586.
5. Caldas C, Kern SE. Related K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 1995;18:1-6.
6. Castells A, Puig P, Mora J et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 1999;17:578-584.
7. Eskelinen M, Haglund U. Developments in serologic detection of human pancreatic adenocarcinoma. Scand J Gastroenterol 1999;34:833-844.
8. Gress TM, Muller-Pillasch F, Geng M et al. A pancreatic cancer-specific expression profile. Oncogene 1996;13:1819-1830.
9. Halm U, Schumann T, Schiefke I et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000;82:1013-1016.
10. Iacobuzio-Donahue CA, Maitra A, Olsen M et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003;162: 1151-1162.
11. Koizumi M, Doi R, Toyoda E et al. Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer. Surgery 2003;134:260-266.
12. Logsdon CD, Simeone DM, Binkley C et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003;63:2649-2657.
13. Luttges J, Diederichs A, Menke MA et al. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53. Cancer 2000;88:2495-2504.
14. Maitra A, Adsay NV, Argani P et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003;16:902-912.
15. Micke O, Bruns F, Schafer U et al. CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 2003;23:835-840.
16. Mu DQ, Wang GF, Peng SY. p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis. World J Gastroenterol 2003;9:1815-1818.
17. Mueller F, Bommer M, Lacher U et al. KOC is a novel molecular indicator of malignancy. Br J Cancer 2003;8:699-701.
18. Ringel J, Faulmann FG, Brandt R et al. MUC4 mRNA in peripheral blood mononuclear cells (PBMC) as a potential tumor marker for pancreatic cancer. Proc ASCO 2001;42:A616.
19. Saad ED, Machado MC, Wajsbrot D et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002;32:35-41.
20. Schlieman, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138:951-955.
21. Slesak B, Harlozinska-Szmyrka A, Knast W et al. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 2000;89: 83-88.
22. Trumper L, Menges M, Daus H et al. Low sensitivity of the ki-ras polymerase chain reaction for diagnosing pancreatic cancer from pancreatic juice and bile: a multicenter prospective trial. J Clin Oncol 2002;20:4331-4337.
23. Uemura K, Hiyama E, Murakami Y et al. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours. Oncol Rep 2003;10:277-283.
24. Xie MJ, Motoo Y, Iovanna JL et al. Overexpression of pancreatitis-associated protein (PAP) in human pancreatic ductal adenocarcinoma. Dig Dis Sci 2003;48:459-464.
25. Yamaguchi Y, Watanabe H, Yrdiran S. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation. Clin Cancer Res 1999;5:1147-1153.